These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 20362759)

  • 1. Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications.
    Bergenstal RM; Bailey CJ; Kendall DM
    Am J Med; 2010 Apr; 123(4):374.e 9 -18. PubMed ID: 20362759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ADVANCE: action in diabetes and vascular disease.
    Patel A; Chalmers J; Poulter N
    J Hum Hypertens; 2005 Jun; 19 Suppl 1():S27-32. PubMed ID: 16075030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycemic targets for patients with type 2 diabetes mellitus.
    Hamnvik OP; McMahon GT
    Mt Sinai J Med; 2009 Jun; 76(3):227-33. PubMed ID: 19421966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic management of the patient with type 2 diabetes.
    Quinn L
    Nurs Clin North Am; 2001 Jun; 36(2):217-42, vi. PubMed ID: 11382561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current controversies in glycemic control targets. What do the results of the latest clinical trials tell us about the approach to type 2 diabetes mellitus?].
    Mauricio D; Rius F
    Med Clin (Barc); 2010 Sep; 135 Suppl 2():2-5. PubMed ID: 21420530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of new diabetes treatment trials: should current clinical practice be altered?
    Kravetz JD; Federman DG
    Postgrad Med; 2009 May; 121(3):67-72. PubMed ID: 19491542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reducing cardiovascular disease risk in patients with type 2 diabetes and concomitant macrovascular disease: can insulin be too much of a good thing?
    Rensing KL; Reuwer AQ; Arsenault BJ; von der Thüsen JH; Hoekstra JB; Kastelein JJ; Twickler TB
    Diabetes Obes Metab; 2011 Dec; 13(12):1073-87. PubMed ID: 21736687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people.
    Schramm TK; Gislason GH; Køber L; Rasmussen S; Rasmussen JN; Abildstrøm SZ; Hansen ML; Folke F; Buch P; Madsen M; Vaag A; Torp-Pedersen C
    Circulation; 2008 Apr; 117(15):1945-54. PubMed ID: 18378618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in the treatment of type II diabetes mellitus.
    Baliga BS; Fonseca VA
    Am Fam Physician; 1997 Feb; 55(3):817-24. PubMed ID: 9048504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The elderly and diabetes: an age trend and an epidemic converging.
    Marquess JG
    Consult Pharm; 2008 Apr; 23 Suppl B():5-11. PubMed ID: 18540787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U; Pop-Busui R; Eagle KA
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents.
    Hauber AB; Mohamed AF; Johnson FR; Falvey H
    Diabet Med; 2009 Apr; 26(4):416-24. PubMed ID: 19388973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of hypoglycemic agents on mortality and major cardiovascular outcomes in patients with type 2 diabetes mellitus: a narrative review [88].
    Miranda VP; Rodrigues MJ; Gonçalves FR; Nunes JP
    Rev Port Cardiol; 2009 Oct; 28(10):1099-119. PubMed ID: 20058777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucokinase activators in diabetes management.
    Coghlan M; Leighton B
    Expert Opin Investig Drugs; 2008 Feb; 17(2):145-67. PubMed ID: 18230050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treating the diabetic patient: appropriate care for glycemic control and cardiovascular disease risk factors.
    Zarich SW
    Rev Cardiovasc Med; 2003; 4 Suppl 6():S19-28. PubMed ID: 14668700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study.
    Du X; Ninomiya T; de Galan B; Abadir E; Chalmers J; Pillai A; Woodward M; Cooper M; Harrap S; Hamet P; Poulter N; Lip GY; Patel A;
    Eur Heart J; 2009 May; 30(9):1128-35. PubMed ID: 19282274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perioperative management of ambulatory surgical patients with diabetes mellitus.
    Vann MA
    Curr Opin Anaesthesiol; 2009 Dec; 22(6):718-24. PubMed ID: 19696663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association between intensive glycemic control and vascular complications in type 2 diabetes mellitus: a meta-analysis.
    Ma J; Yang W; Fang N; Zhu W; Wei M
    Nutr Metab Cardiovasc Dis; 2009 Nov; 19(9):596-603. PubMed ID: 19819121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of pioglitazone on the drivers of cardiovascular risk in type 2 diabetes.
    Donnelly R
    Int J Clin Pract; 2007 Jul; 61(7):1160-9. PubMed ID: 17511791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting the effects of blood pressure-lowering treatment on major cardiovascular events for individual patients with type 2 diabetes mellitus: results from Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation.
    van der Leeuw J; Visseren FL; Woodward M; Zoungas S; Kengne AP; van der Graaf Y; Glasziou P; Hamet P; MacMahon S; Poulter N; Grobbee DE; Chalmers J
    Hypertension; 2015 Jan; 65(1):115-21. PubMed ID: 25312436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.